文献速递免疫规划卫生政策与健康促进

肺炎球菌疫苗接种在控制抗菌素耐药性发展中的价值:埃塞俄比亚DREAMR案例研究

Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia.
PubMed 文献 · Vaccine · 2021-09-17

该研究开发了基于智能体的DREAMR模型,评估埃塞俄比亚儿童肺炎球菌结合疫苗(PCV)接种对减缓抗菌素耐药性(AMR)发展的经济价值。模型整合接种覆盖率、疾病发病率、就医行为和抗生素使用,基于药代动力学和药效学模拟AMR积累。结果显示PCV接种减缓了阿莫西林和头孢曲松的AMR发展,并避免了大量抗生素治疗失败和AMR相关死亡,带来显著成本节约。

要点

  • PCV接种减缓埃塞俄比亚阿莫西林AMR发展14.77%,头孢曲松0.59%。
  • 2011-2017年PCV接种避免约718,100例抗生素治疗失败和9,520例AMR相关死亡。

核心结论

  • 本研究首次证明肺炎球菌疫苗接种在非洲控制AMR发展中具有更广泛的经济价值。
  • 疫苗接种不仅通过预防疾病挽救生命,还通过减少抗生素使用和AMR导致的治疗失败使社会受益。

研究设计与样本

  • 研究开发了基于智能体的DREAMR模型,整合疫苗接种覆盖率、疾病发病率、就医行为和抗生素使用。
  • 模型基于药代动力学和药效学模拟抗生素暴露导致的AMR积累,并应用于埃塞俄比亚。

主要发现

  • 自2011年引入PCV以来,埃塞俄比亚阿莫西林AMR发展减缓14.77%,头孢曲松减缓0.59%。
  • 2011年至2017年间,PCV接种避免了约718,100例抗生素治疗失败和9,520例AMR相关死亡(减少27.8%)。

临床怎么用

  • 将PCV接种作为控制AMR的综合策略之一,不仅评估其疾病预防效果,还应纳入AMR相关经济收益。
  • 维持并提高PCV覆盖率可带来持续的健康和经济收益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance (AMR) poses an imminent threat to global health security. Pneumococcal vaccination reduces disease incidence, prevents antibiotic use, and decreases antibiotic-resistant infections. However, the benefit of vaccination in reducing AMR has been poorly quantified to date. METHODS: We developed an agent-based model, DREAMR (Dynamic Representation of the Economics of AMR) to evaluate the economic value of childhood immunization with the pneumococcal conjugate vaccine (PCV) in mitigating the development of AMR. Our model incorporates vaccination coverage, disease incidence, care seeking, and antibiotic use. Accumulation of AMR is simulated based on antibiotic exposure through pharmacokinetics and resulting pharmacodynamics. The model was applied to Ethiopia. RESULTS: Introduction of PCV vaccination has helped slow the development of AMR by 14.77% for amoxicillin and 0.59% for ceftriaxone in Ethiopia since 2011. In addition to the benefit of reduction in disease incidence, PCV vaccination has averted approximately 718,100 antibiotic treatment failures and 9,520 AMR-related deaths (27.8% reduction) in Ethiopia between 2011 and 2017, resulting in savings of $32.7 million. Maintaining current PCV immunization coverage will contribute an additional $7.67 million in annual AMR cost savings over five years compared to no vaccination scenario, which could increase to $11.43 million by increasing PCV coverage to 85% by 2022. CONCLUSIONS: This study is the first to demonstrate the broader economic value of pneumococcal vaccination in controlling the development of AMR in Africa. Vaccination not only saves lives by preventing illnesses, but also benefits society by reducing antibiotic utilization and treatment failures due to AMR.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ozawa S, Chen HH, Rao GG, et al. Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia. Vaccine. 2021. PMID: 34538697. doi:10.1016/j.vaccine.2021.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。